WO2005072055A9 - Nouveaux variants de peptides cerebraux natriuretiques et leurs procede d'utilisation - Google Patents
Nouveaux variants de peptides cerebraux natriuretiques et leurs procede d'utilisation Download PDFInfo
- Publication number
- WO2005072055A9 WO2005072055A9 PCT/IB2005/000995 IB2005000995W WO2005072055A9 WO 2005072055 A9 WO2005072055 A9 WO 2005072055A9 IB 2005000995 W IB2005000995 W IB 2005000995W WO 2005072055 A9 WO2005072055 A9 WO 2005072055A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- natriuretic peptide
- brain natriuretic
- peptide variants
- novel brain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2005207886A AU2005207886A1 (en) | 2004-01-27 | 2005-01-27 | Novel brain natriuretic peptide variants and methods of use thereof |
EP05718453A EP1730181A2 (fr) | 2004-01-27 | 2005-01-27 | Nouveaux variants de peptides cerebraux natriuretiques et leurs procede d'utilisation |
CA002554599A CA2554599A1 (fr) | 2004-01-27 | 2005-01-27 | Nouveaux variants de peptides cerebraux natriuretiques et leurs procede d'utilisation |
JP2006550367A JP2007525213A (ja) | 2004-01-27 | 2005-01-27 | 新規の脳性ナトリウム利尿ペプチドの変異体及びその利用方法 |
Applications Claiming Priority (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53912704P | 2004-01-27 | 2004-01-27 | |
US60/539,127 | 2004-01-27 | ||
US58785104P | 2004-07-15 | 2004-07-15 | |
US60/587,851 | 2004-07-15 | ||
US60724604P | 2004-09-07 | 2004-09-07 | |
US60/607,246 | 2004-09-07 | ||
US60/622,320 | 2004-10-25 | ||
US62232004P | 2004-10-27 | 2004-10-27 | |
US62201604P | 2004-10-27 | 2004-10-27 | |
US60/622,016 | 2004-10-27 | ||
US62819004P | 2004-11-17 | 2004-11-17 | |
US60/628,190 | 2004-11-17 | ||
US11/043,590 | 2005-01-27 | ||
US11/043,590 US7332569B2 (en) | 2004-01-27 | 2005-01-27 | Brain natriuretic peptide spliced variant |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005072055A2 WO2005072055A2 (fr) | 2005-08-11 |
WO2005072055A9 true WO2005072055A9 (fr) | 2011-02-17 |
Family
ID=34831546
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2005/000995 WO2005072055A2 (fr) | 2004-01-27 | 2005-01-27 | Nouveaux variants de peptides cerebraux natriuretiques et leurs procede d'utilisation |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1730181A2 (fr) |
AU (1) | AU2005207886A1 (fr) |
CA (1) | CA2554599A1 (fr) |
WO (1) | WO2005072055A2 (fr) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1638443T3 (da) | 2003-06-20 | 2011-02-07 | Mayo Foundation | Isoformer af hjerne-natriuretisk peptid |
HUE039448T2 (hu) | 2004-04-21 | 2018-12-28 | Alexion Pharma Inc | Csontba szállító konjugátumok és alkalmazási módszerük a fehérjék csontba juttatására |
CA2647143A1 (fr) | 2006-03-30 | 2007-10-11 | Palatin Technologies, Inc. | Constructions de peptides natriuretiques cycliques |
JP5702930B2 (ja) | 2006-08-08 | 2015-04-15 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | 利尿ポリペプチドおよびナトリウム利尿ポリペプチド |
WO2008031045A2 (fr) | 2006-09-08 | 2008-03-13 | Mayo Foundation For Medical Education And Research | Polypeptides aquarétiques et natriurétiques dépourvus d'activité vasodilatatoire |
US9086408B2 (en) | 2007-04-30 | 2015-07-21 | Nexus Dx, Inc. | Multianalyte assay |
WO2009036448A2 (fr) | 2007-09-15 | 2009-03-19 | Mayo Foundation For Medical Education And Research | Agonistes des récepteurs peptidiques natriurétiques de type c |
TWI686405B (zh) | 2008-12-09 | 2020-03-01 | 建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
RU2572694C2 (ru) | 2009-07-23 | 2016-01-20 | ИГИСУ Ко., Лтд. | Композиция кожного препарата для наружного применения |
BR112012004058A2 (pt) | 2009-08-27 | 2021-08-17 | Kyoko Endo | preparação terapêutica para rinite |
EP2658979B1 (fr) | 2010-12-27 | 2018-02-14 | Alexion Pharmaceuticals, Inc. | Compositions contenant des peptides natriurétiques et leurs méthodes d'utilisation |
ES2647680T3 (es) | 2011-01-21 | 2017-12-26 | Igisu Co., Ltd. | Fármaco terapéutico para la alopecia |
SG10201601086WA (en) * | 2011-08-18 | 2016-03-30 | Otago Innovation Ltd | Cardiovascular therapeutics |
CN103906761B (zh) | 2011-08-30 | 2016-12-21 | 梅约医学教育与研究基金会 | 利钠多肽 |
US9611305B2 (en) | 2012-01-06 | 2017-04-04 | Mayo Foundation For Medical Education And Research | Treating cardiovascular or renal diseases |
US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
WO2016007873A1 (fr) | 2014-07-11 | 2016-01-14 | The Regents Of The University Of Michigan | Compositions et méthodes de traitement de la craniosynostose |
JP6787894B2 (ja) | 2014-12-05 | 2020-11-18 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 組換えアルカリホスファターゼを用いた発作の処置 |
AU2016211447B2 (en) | 2015-01-28 | 2021-09-23 | Alexion Pharmaceuticals, Inc. | Methods of treating a subject with an alkaline phosphatase deficiency |
KR102644116B1 (ko) | 2015-08-17 | 2024-03-05 | 알렉시온 파마슈티칼스, 인코포레이티드 | 알칼린 포스파타제의 제조 |
EP3355904A4 (fr) | 2015-09-28 | 2019-06-12 | Alexion Pharmaceuticals, Inc. | Identification de régimes posologiques efficaces pour une thérapie de l'hypophosphatasie de remplacement de l'enzyme phosphatase alcaline non spécifique à des tissus (tnsalp) |
EP3368062A4 (fr) | 2015-10-30 | 2019-07-03 | Alexion Pharmaceuticals, Inc. | Méthodes de traitement de la craniosynostose chez un patient |
EP3426286A4 (fr) | 2016-03-08 | 2019-12-04 | Alexion Pharmaceuticals, Inc. | Méthodes de traitement de l'hypophosphatasie chez l'enfant |
EP3436020A4 (fr) | 2016-04-01 | 2019-12-25 | Alexion Pharmaceuticals, Inc. | Méthodes de traitement de l'hypophosphatasie chez les adolescents et les adultes |
MX2018011833A (es) | 2016-04-01 | 2019-02-13 | Alexion Pharma Inc | Tratamiento para la debilidad muscular con fosfatasas alcalinas. |
US10988744B2 (en) | 2016-06-06 | 2021-04-27 | Alexion Pharmaceuticals, Inc. | Method of producing alkaline phosphatase |
US11116821B2 (en) | 2016-08-18 | 2021-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating tracheobronchomalacia |
US9611297B1 (en) | 2016-08-26 | 2017-04-04 | Thrasos Therapeutics Inc. | Compositions and methods for the treatment of cast nephropathy and related conditions |
AU2018243320A1 (en) | 2017-03-31 | 2019-10-10 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia (HPP) in adults and adolescents |
WO2019190752A1 (fr) | 2018-03-30 | 2019-10-03 | Alexion Pharmaceuticals, Inc. | Production de glycoprotéines |
-
2005
- 2005-01-27 EP EP05718453A patent/EP1730181A2/fr not_active Withdrawn
- 2005-01-27 AU AU2005207886A patent/AU2005207886A1/en not_active Abandoned
- 2005-01-27 WO PCT/IB2005/000995 patent/WO2005072055A2/fr active Application Filing
- 2005-01-27 CA CA002554599A patent/CA2554599A1/fr not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1730181A2 (fr) | 2006-12-13 |
AU2005207886A1 (en) | 2005-08-11 |
WO2005072055A2 (fr) | 2005-08-11 |
CA2554599A1 (fr) | 2005-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005072055A9 (fr) | Nouveaux variants de peptides cerebraux natriuretiques et leurs procede d'utilisation | |
EP1838331A4 (fr) | Peptides antimicrobiens et procedes d'utilisation associes | |
ME02245B (me) | Anti-cd38 humana antitjela i njihove upotrebe | |
IL213843A0 (en) | 4-aminotetracyclines and methods of use thereof | |
EP1636250A4 (fr) | Peptides autoassembles presentant des modifications et methodes d'utilisation des peptides | |
IL178593A (en) | Specific antibodies of fcγriib and methods for their use | |
EP1744744A4 (fr) | Composes bioactifs et procedes de leur utilisation | |
EP1794589A4 (fr) | Reseaux de proteines et leurs procedes d'utilisation | |
AU2003265522A1 (en) | FCGammaRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | |
SI2511297T1 (sl) | Proti -CD38 humana protitelesa in njihova uporaba | |
IL176958A0 (en) | Compounds and methods of use | |
EP1660013A4 (fr) | Biomateriaux et biocoacervats proteiniques, leurs procedes de fabrication et d'utilisation | |
ZA200607582B (en) | Anti-parasitic compounds and methods of their use | |
SI1587542T1 (sl) | Uporaba anti-cd100 protiteles | |
IL173736A0 (en) | Process for the preparation of renzapride and intermediates thereof | |
EP1812451A4 (fr) | Composes et methodes d'utilisation de ces composes | |
ZA200606319B (en) | Anti-CD38 human antibodies and uses therefor | |
EP1735281A4 (fr) | Synthese d'indenoisoquinoliniums et techniques d'utilisation | |
ZA200510465B (en) | Use of a novel eimeria gene and corresponding protein | |
EP1633749A4 (fr) | Composes de deazaflavine et leurs methodes d'utilisation | |
GB2401094B (en) | Labels and methods of manufacture thereof | |
IL177868A0 (en) | Anti-inflammatory peptides and methods of use thereof | |
WO2005033343A8 (fr) | Nouveaux variants d'epissage du gene dkkl1 humain | |
AU2003287802A1 (en) | Palpometer and methods of use thereof | |
EP1802560A4 (fr) | Halocombstatines et leurs methodes de synthese |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2554599 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006550367 Country of ref document: JP |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005207886 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
ENP | Entry into the national phase in: |
Ref document number: 2005207886 Country of ref document: AU Date of ref document: 20050127 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005207886 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005718453 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005718453 Country of ref document: EP |